What is Ablexis?
Ablexis operates at the forefront of biotechnology, offering a sophisticated transgenic mouse platform engineered for the efficient discovery and development of therapeutic antibodies. Their proprietary AlivaMab-X Mouse technology is designed to yield expanded immune responses, positioning Ablexis as a key partner for pharmaceutical and biotechnology firms focused on novel antibody-based drug candidates. The company also provides flexible licensing options, catering to the specific requirements of its collaborators in the competitive landscape of drug development.
How much funding has Ablexis raised?
Ablexis has raised a total of $12M across 1 funding round:
Series A
$12M
Series A (2010): $12M with participation from Third Rock Ventures
Key Investors in Ablexis
Third Rock Ventures
Third Rock Ventures is a prominent healthcare venture capital firm established in 2007, dedicated to identifying and nurturing disruptive scientific and medical innovations. They focus on building companies that aim to significantly improve patient outcomes through a combination of scientific insight, strategic leadership, and operational expertise.
What's next for Ablexis?
The enterprise-level funding context suggests Ablexis is in a growth phase, likely focused on scaling its platform capabilities and expanding its market reach. The recent strategic investment indicates a strong belief in the company's technology and its potential to accelerate the pipeline of antibody-based therapeutics. Future endeavors will probably involve further platform enhancement, strategic partnerships, and the continued support of drug discovery initiatives within the biopharmaceutical sector.
See full Ablexis company page
